title: Bioactivities of Fas ligand-expressing retroviral particles.
abstract: Culture supernatants from retroviral packaging cells carrying the human Fas ligand (FasL) gene killed both human (Jurkat) and mouse (LB27.4) targets within 5 h of incubation. Cytotoxicity was found both in a fraction >/=500 kDa and a fraction between 50 and 500 kDa. Following ultracentrifugation, the activity in the >/=500-kDa fraction was concentrated in the pellet (FasL vector preparation (VP)), which was also infective when added to NIH-3T3 cells. Both Polybrene and poly-l -lysine significantly enhanced the cytotoxicity of FasL VP but not anti-Fas mAb, soluble FasL (sFasL), and cell-associated FasL. In the presence of Polybrene, FasL VP killed targets that are resistant to anti-Fas mAb and sFasL. The infectivity but not FasL cytotoxicity of FasL VP was sensitive to irradiation and heat shock. By contrast, cytotoxicity of FasL VP could be enhanced or inhibited depending on the doses of anti-FasL mAb. Interestingly, the infectivity of FasL VP was specifically enhanced by anti-FasL mAb, suggesting that a nonviral gene product could be used to regulate the behavior of the retroviral vector. Thus, in addition to expressing potent FasL cytotoxicity, the FasL VP exhibits unique properties heretofore not attributed to anti-Fas mAb, sFasL, and cell-associated FasL. Our study raises the possibility of using the retroviral gene-packaging technology to make powerful, versatile, and regulatable bioactive vesicles expressing a predetermined function of the protein encoded by the target gene.
authors.affiliation: Arthritis Center, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
authors.forename: S
authors.initials: S
authors.lastname: Jodo
authors.forename: D
authors.initials: D
authors.lastname: Strehlow
authors.forename: S T
authors.initials: ST
authors.lastname: Ju
mesh_terms: D016475:3T3 Cells; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D002474:Cell-Free System / Q000276:immunology; D003602:Cytotoxicity, Immunologic / Q000187:drug effects / Q000235:genetics; D053222:Fas Ligand Protein; D015967:Gene Expression Regulation, Viral / Q000187:drug effects / Q000276:immunology; D005822:Genetic Vectors / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism; D006583:Hexadimethrine Bromide / Q000494:pharmacology; D006801:Humans; D008024:Ligands; D008562:Membrane Glycoproteins / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D051379:Mice; D008979:Moloney murine leukemia virus / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D014771:Virion / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D019065:Virus Assembly / Q000235:genetics / Q000276:immunology; D019014:fas Receptor / Q000235:genetics / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; C505661:FASLG protein, human; D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D008024:Ligands; D008562:Membrane Glycoproteins; D019014:fas Receptor; D006583:Hexadimethrine Bromide